Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Gastroparesis

Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine. Gastroparesis is caused when vagus nerve is damaged or stops working. The vagus nerve gets damaged if someone has diabetes and blood sugar or blood glucose levels stay high over a long period of time.

The vagus nerve controls how food moves through digestive tract. When this nerve doesn’t work well, food moves too slowly or stops moving.

Other causes of gastroparesis include: anorexia or bulimia, chronic fatigue syndrome, amyloidosis, scleroderma, Parkinson's disease, abdominal migraine, hypothyroidism

Gastroparesis can be classified into three types:

Diabetic gastroparesis

Idiopathic gastroparesis

Post-surgical gastroparesis

Epidemiology- According to Thelansis, Gastroparesis affects approximately 4% of the population and is more common in women. Many people with gastroparesis also have diabetes, and 50% of those affected had diabetes before the onset of their gastroparesis.

Competitive landscape of Gastroparesis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Gastroparesis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Gastroparesis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        Velusetrag        Theravance Biopharma        Phase 2

2        CNSA-001        PTC Therapeutics        Phase 2

3        CIN-102        CinDome Pharma, Inc.        Phase 2

4        Tradipitant        Vanda Pharmaceuticals        Phase 3

5        Camicinal        GlaxoSmithKline        Phase 2

6        Nimacimab        Bird Rock Bio, Inc.        Phase 2

7        Metoclopramide Nasal Spray        Evoke Pharma        Phase 3

8        Neurogastrx, Inc.        Neurogastrx, Inc.        Phase 2

9        IW-9179        Ironwood Pharmaceuticals, Inc.        Phase 2

10        TAK-906 Maleate        Takeda        Phase 2

11        Itopride        Forest Laboratories        Phase 2

12        RM-131        Motus Therapeutics, Inc.        Phase 2

13        Relamorelin        Allergan        Phase 2"